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Background: Use of immune checkpoint inhibitors have improved survival in patients 
suffering from cancer types such as advanced melanoma and NSCLC. Through increased 
understanding of immunological reactions associated with radiotherapy, a potential for 
synergy of radiotherapy and immune checkpoint inhibitors has emerged. Preclinical proof-
of-concept studies have confirmed synergy of the treatments in mouse models.  
Objectives: The primary objective was to identify proof-of-concepts in human data 
supporting combinations of radiotherapy and immune checkpoint inhibition, and identify 
characteristics of potential examples. A secondary objective was to assess if larger patient 
materials supported synergistic effects of such treatment regimens.  
Methods: A literature search in PubMed was conducted to identify original data on patients 
treated with combinations of radiotherapy and immune checkpoint inhibition.  
Results and discussion: Six case reports described impressive treatment responses following 
radiotherapy and immune checkpoint inhibition. A large double blinded RCT, including 799 
patients, failed to present evidence for improved median survival in metastatic castration 
resistant prostate cancer (11,2 months for radiotherapy and Ipilimumab vs. 10,0 months for 
radiotherapy and placebo). Seven retrospective studies on patients (n=200) with advanced 
melanoma showed median survival over the expected, while two (n=38) failed to do so. 
Three of the retrospective studies specifically looked radiographically for abscopal responses 
outside the irradiated field, noting unusually frequent responses.  A single small prospective 
trial (n=22) on advanced melanoma did not find a median survival over the expected. The 
studies varied in characteristics of the patient populations, methodologies and in 
radiotherapy regimens.  
Conclusion: Case reports and retrospective studies investigating abscopal responses after 
radiation presented circumstantial evidence for synergy of radiotherapy and immune 
checkpoint inhibition. The single identified randomized controlled trial failed to prove 
increased survival of a relevant combination regimen in metastatic castration resistant 




CD – cluster of differentiation 
TH cells – T helper cells 
APC – antigen presenting cell 
TCR – T cell receptor 
MHC – major histocompatibility complex 
IL – interleukin  
CTLA-4 – cytotoxic T lymphocyte-associated protein 4  
Tregs – regulatory T cells 
PD-1 – programmed cell death 1  
TGFβ – transforming growth factor β 
PD-L1/2 – programmed cell death ligand 1/2 
mAb – monoclonal antibody 
MS – median survival 
NSCLC – non-small-cell lung cancer 
FDA – U.S. Food and Drug Administration  
ATP – adenosine triphosphate  
RT – radiotherapy 
PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
OF – out of radiation field  
IF – in radiation field  
CR – complete response 
PR – partial response 
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SD – stable disease 
MeSH - Medical Subject Headings 
mCRPC – metastatic castration resistant prostate cancer 
IMRT – intensity modulated radiotherapy  
WBRT – whole brain radiotherapy 
SRS – stereotactic radiosurgery 
SABR - Stereotactic ablative radiotherapy 
Gy – Gray (unit) 
CT – computed tomography 
PET-CT – positron emission tomography – computed tomography 
CNS – central nervous system 
HR – hazard ratio 
ICOS – inducible T cell costimulator 
HLA-DR – human leukocyte antigen – antigen D related 





Radiation Regimens:  
The American National Cancer Institute defines stereotactic radiosurgery as (1); “A type of 
external radiation therapy that uses special equipment to position the patient and precisely 
give a single large dose of radiation to a tumor. It is used to treat brain tumors and other 
brain disorders that cannot be treated by regular surgery.” 
The American National Cancer Institute defines intensity-modulated radiation therapy as (1); 
“A type of 3-dimensional radiation therapy that uses computer-generated images to show 
the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at 
the tumor from many angles. This type of radiation therapy reduces the damage to healthy 
tissue near the tumor.” 
The American National Cancer Institute defines stereotactic body radiation therapy (also 
known as stereotactic ablative radiation therapy (2), which is the term that will be used in 
the present review) as (1); “A type of external radiation therapy that uses special equipment 
to position a patient and precisely deliver radiation to tumors in the body (except the brain). 
The total dose of radiation is divided into smaller doses given over several days. This type of 
radiation therapy helps spare normal tissue.”  
Abscopal: 
The term derives from greek, ab: away from, scopus: target, abscopal: away from target. The 
word describes effects of radiation in non-irradiated tissue distant from the irradiated tissue 
(3).  
Immune Checkpoint Inhibitors: 
The American National Cancer Institute describe immune checkpoint inhibitors as (1); “A 
type of drug that blocks certain proteins made by some types of immune system cells, such 
as T cells, and some cancer cells. These proteins help keep immune responses in check and 
can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on 
the immune system are released and T cells are able to kill cancer cells better. Examples of 
checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-
2. Some immune checkpoint inhibitors are used to treat cancer.”  
7 
 
Measures of Treatment Response:  
The American National Cancer Institute defines response as (1); “In medicine, an 
improvement related to treatment.” The corresponding definition of objective response is; 
“A measurable response.”  
To make reporting of results of cancer treatments more similar, several sets of response 
criteria exist for consistent reporting of objective responses measured radiographically. 
WHO-criteria (4), Response Evaluation Criteria in Solid Tumors (RECIST) (5) and Immune-
Related Response Criteria (6) are examples of such criteria. A complete response is a 
complete disappearance of target lesions. A partial response is a shrinkage in measurements 
of tumor size over a certain defined threshold, while stable disease is small changes in size in 
either direction. Progressive disease an increase in measurements of tumor size over a 
certain defined threshold. The exact measurements and thresholds varies somewhat 
between the three mentioned criteria. Of note, the Immune-Related Response Criteria is 
designed for following responses to immune-checkpoint inhibitors, due to unusual response 
patterns, with so-called initial pseudoprogression of tumors sometimes occurring, followed 





Tumor immunology and immune checkpoints  
While the hypothesis of the immune system protecting against cancer is more than 100 
years old, with Paul Erlich as an early proponent in 1909 (7), solid evidence for the theory did 
not emerge before the end of the 20th century. In a paper published in 2004, Dunn et al 
reviewed the process of accumulating evidence leading up to the resurrection of the cancer 
immunosurveillance theory (8). Not only did the new evidence indicate protective anti-tumor 
effects of the immune system, but preclinical evidence also suggested that the immune 
system shaped the properties of the cancer. When tumors where transplanted from immune 
deficient mice to immunocompetent ones, the new hosts rejected the tumor transplants far 
more often than they rejected tumor transplants originally grown in immunocompetent 
hosts (9-11). This suggested that mice with a competent immune system was exerting a 
selective pressure on the tumor, leading to the evolution of less immunogenic tumor 
phenotypes in these mice. The realization that the immune system was not only protecting 
the mice from cancer, but also shaping the properties of the cancer, led Dunn et al to 
propose a refined model, which they termed cancer immunoediting (8). If the immune 
system had effective mechanisms for killing cancer cells and suppressing tumor growth, it 
followed logically that any clinically recognized cancer would somehow have been “edited” 
and subsequently escaped from this suppression (8). 
A major focus in tumor immunology has therefore been to identify the mechanisms 
underlying the ability of cancers to avoid destruction by immune system. Due to the 
centrality of the adaptive immune system in forming specific responses, T-cell suppressive 
mechanisms have received special interest, reviewed in ref. (12). The ability of T cells to 
monitor the internal contents of cells by interacting very specifically with antigen peptides 
presented on major histocompatibility complexes (MHC) makes them ideal candidates to 
detect and respond to the fine-grained differences between normal cells and transformed 
cancer cells. Both cytotoxic cluster of differentiation (CD) 8 positive T cells and CD4 helper 1 
T cells (TH1 cells) are effector cells implicated in eliciting anti-tumor immunity (12).  
An important checkpoint in activation of a specific T cell response is the interaction of a 
professional antigen-presenting cell (APC) and the naïve T-cell (12). Interaction between a 
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specific T cell receptor (TCR) and a peptide antigen on a MHC-II molecule is not in itself 
enough for activation and subsequent proliferation of the T cell, and additional co-
stimulatory signaling is required. This process is a complicated interplay between a number 
of ligands and receptors. One of these co-stimulatory signaling pathways is mediated by the 
ligands B7.1 and B7.2. These are expressed by APCs, and interact with the receptor CD28 on 
the T cell surface, presenting a stimulatory signal. If the stimulation is strong enough, the T 
cell clone will produce copious amounts of interleukin (IL) 2 and proliferate, reviewed in ref. 
(13). However, the B7 ligands also serve as ligands for the cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4). On CD4+ T-cells and CD8+ T cells, CTLA-4 is induced on the surface after 
TCR and CD28 engagement, where it serves as a regulator of negative feedback, inhibiting 
proliferation, reviewed in ref. (14). CTLA-4 is expressed constitutively on T regulatory cells 
(Tregs) (15, 16), and through CTLA-4-mediated activity these cells can suppress effector T cell 
activity and proliferation (14). One mechanism for this suppression, explored in vitro and in 
mice models, is downregulation of B7.1/2 on APCs by “stealing” of these ligands by 
endocytosis of the CTLA-4/ligand complex, into the lymphocyte bearing CTLA-4 following 
binding (17). Tregs are also mediating potent immunosuppressive effects on effector T cells 
via secretion of cytokines such as TGFβ, induced by activation of CTLA-4 (18).  
Another inhibitory molecule is the programmed cell death 1 receptor (PD-1), reviewed in ref. 
(19). It is found on T cells, natural killer cells, B cells and myeloid-derived cells. By interacting 
with the programmed death ligand 1 (PD-L1) or programmed death ligand 2 (PD-L2), 
signaling through this receptor lead to T cell exhaustion and unresponsiveness, inhibiting 
effective T cell mediated responses. Unlike the CTLA-4 axis, where ligands are found on 
APCs, the ligands for the PD-1 receptor can be found in a wider range of cells, including 
cancer cells (20, 21).  
Preclinical experiments as well as clinical evidence have implicated that CTLA-4 and PD-1 
mediated signaling is indeed of importance in shielding cancers from attack by effector T 
cells, as reviewed in ref. (22), and collectively these types of signal molecules that can turn 




Immune checkpoint inhibitors 
Since hijacking of the CTLA-4 and PD-1 signaling axes are important means for tumors to 
escape immunosurveillance, these receptors, and in the case of PD-1 its ligands, presented 
interesting targets for blockade with monoclonal antibodies (mAb). In two landmark clinical 
trials, inhibition of CTLA-4 with the mAb Ipilimumab, led to a significant increase in median 
survival (MS) in patients treated with Ipilimumab compared to control groups (23, 24). This 
was the first time a drug had been shown to consistently increase survival in advanced 
melanoma, and some patients have experienced very durable responses. A pooled analysis 
of survival data from 1861 patients found a plateau on the Kaplan-Meier survival curve 
starting from 3 years, extending for several additional years for some patients. The 3-year 
survival rate was 22% (25).  
Later, randomized controlled trials have shown treatment benefits of the anti-PD-1 mAb 
Nivolumab and the anti-PD-L1/2 mAb Pembrolizumab in advanced melanoma (26-28), non-
small-cell lung carcinoma (NSCLC) (29-31), and in the case of Nivolumab in advanced renal 
cell carcinoma (32). A randomized controlled trial has also shown increased progression free 
survival when treating patients with a combination of Nivolumab and Ipilimumab compared 
to monotherapies of each (33).  
While there has been a number of clinical trials showing benefits of immune checkpoint 
inhibitors in different types of advanced cancer, responses are limited to a subset of 
patients. In the two landmark trials with patients treated with Ipilimumab, the percentage of 
patients with partial or complete responses, or stable disease, was modest at a rate of 28,5% 
in one of the trials and 33,2% in the other (23, 24). Therefore, while the success of immune 
checkpoint inhibitors is a major breakthrough, there is still a need to increase the number of 
patients experiencing durable anti-tumor responses.   
Radiotherapy and tumor immunology 
In 1953, Mole coined the term abscopal effect to describe distant biological effects of 
radiation outside of the irradiated tissue field (3). Throughout the years, a number of case 
reports have described patients suffering from cancer, where irradiation of one tumor is 
followed by remission of tumor masses outside of the irradiated field, as reviewed in these 
articles (34, 35). Direct tumoricidal effects of the radiation can obviously not cause these 
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responses, and evidence points to the immune system as the mediator of these abscopal 
effects, as reviewed by Formenti and Demaria in 2013 (36). Direct killing of cancer cells by 
radiation lead to the translocation of the immunogenic marker calreticulin to the surface of 
the dying cell, as well as release of immunological danger signals such as high-mobility group 
protein B1 and ATP. With propagation of these signals, the cancer cells die in a manner that 
has been termed immunogenic cell death, due to the ability of these signals to trigger an 
immune response (37-39). Killing of cancer cells also expose tumor antigens, which can form 
the basis of recognition of the cancer cells as so-called non-self by the adaptive immune 
system, as opposed to the immunologically tolerated self (40). Presentation of these 
antigens by dendritic cells activated by danger signals can prime tumor specific T cells (41). 
Thus, radiation can provide a vaccine-like effect (36).   
As local effects, radiation can also induce increased expression of MHC-I, which allows for 
better monitoring of tumor antigens by cytotoxic CD8+ T cells (42, 43). Adhesion molecules 
and stress-induced ligands have also been found to have increased expression on the surface 
of cancer cells following irradiation (44, 45). In addition, experimental models have shown 
increased production of chemokines attracting effector T cells (46, 47). Altogether, this 
might lead to increased responsiveness to immunological attack. However, the fact that 
abscopal responses are rare, suggests that most clinically detectable cancers have developed 
tumor microenvironments that are so immunosuppressive, that even the aforementioned 
vaccine-like effect of radiotherapy (RT) is not enough to elicit an effective adaptive immune 
response on its own (36).  
Intersection between radiotherapy and immune checkpoint inhibition 
Based on the ability of RT to provide a vaccine-like boost to the immune system, a rationale 
emerges for combining RT with immune checkpoint inhibitors, which have the potential to 
remove suppressive brakes inhibiting the immune system. Thereby a paper published in 
2005 by Demaria et al. (48) described a set of experiments presenting the first preclinical 
proof-of-principle for synergism between RT and immune checkpoint inhibition. They 
injected the mammary cancer cell line 4T1 subcutaneously into the flank of mice, from 
where metastases spread to the lungs. By comparing mice receiving either a) no treatment, 
b) local RT in a single dose to the primary tumor, c) an inhibitory monoclonal antibody (mAb) 
against CTLA-4, or d) a combination of local RT and inhibition of CTLA-4, the authors found a 
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significant survival benefit in the mice receiving combination therapy. However, the 
researchers also noticed that growth of the irradiated primary tumor was not significantly 
inhibited by the combination therapy, compared to RT alone. Reasoning that the survival 
benefit of the combination therapy was due to an increased systemic control of metastases, 
they used a dissection microscope to count the number of metastases present in the lungs of 
their mice post-sacrifice. Consistent with the survival benefit, the combination regimen did 
indeed lead to a significant decrease in metastases.  
This elegant study design, with controls for both the effect of radiotherapy alone and 
immune checkpoint inhibition alone, strongly suggested that the observed treatment effect 
was more than simply the sum of the individual parts. In subsequent years, a small number 
of clinical studies have been published showing dramatic abscopal treatment responses after 
radiotherapy and inhibition of CTLA-4, which could represent similar phenomena in humans. 
Objectives of the review 
This study aims to review the available clinical evidence of synergistic effects of 
combinatorial treatment regimens of radiotherapy and immune checkpoint inhibitors. The 
main goal is to identify proof-of-concepts in human data supporting such combination 
regimens, assess what characterizes these regimens, and discuss how they fit together with 
preclinical data. A secondary goal is to assess whether any available larger patient materials 
show trends supporting synergism of these two treatment modalities. The layout of this 
thesis is based on the guidelines present in the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement (49), with some modifications. The review 
will span distinct fields of evidence, with several different types of cancers, and different 
drugs and radiation regimens. Direct quantitative synthesis of the results is therefore not 
possible, and thus meta-analysis of the results will not be performed. The goal is to provide a 
qualitative synthesis of results, with a discussion of possible future directions of research. 





Eligibility criteria  
The primary criteria for inclusion of articles in the analysis were that the article should 
include original clinical data dealing with combinations of RT and immune checkpoint 
inhibitors. According to the main objective, identifying proof-of-concepts from clinical data, 
case reports were considered most relevant, given the more comprehensive reporting on 
individual patients than what is typically found in larger clinical studies. To decide what could 
potentially constitute a proof-of-concept, the following set of criteria was defined for 
inclusion of case reports:  
1. The clinical data should show abscopal effects, indicating that any anti-tumor activity 
is not simply a local effect of the RT. This abscopal effect might be: A complete or 
partial response or unusually long stable disease, as defined by the WHO Response 
Criteria, the Response Evaluation Criteria in Solid Tumors (RECIST) or the Immune 
related Response Criteria (4-6). Trying to disentangle synergistic systemic effects 
from effects of the immunotherapy alone, or abscopal effects of RT alone, is far more 
difficult, and will be assessed in the discussion rather than at the eligibility level.  
2. There must be a close temporal relationship between the two treatment modalities. 
One systematic review of abscopal effects after radiation reviewing 46 case reports 
reported a median time of 2 months before the effects manifested (34). Another 
systematic review of 23 case reports plus one retrospective study reported a median 
time of 5 months (35). Based on this, for articles to be included in the present study I 
have set a cut-off of 6 months from RT to treatment with immune checkpoint 
inhibitors.  
3. Lack of confounding treatment: Studies describing patients treated with concurrent 
additional cytotoxic or targeted therapy were excluded. Subsequent cytotoxic or 
targeted therapy were also a cause for exclusion, unless a response appeared before 
the subsequent treatment.  
Since my secondary objective was to review whether any larger patient materials published 
show a trend towards synergism of the two treatment modalities, studies fulfilling the 
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primary criteria and including several patients were also analyzed. Papers published after 
01.01.2005 were included. Only full text papers written in English were reviewed.  
Search strategy  
( OR OR OR OR  OR )AND NOT 
CTLA-4 
antigen 
Programmed cell death 1 
receptor 
CD274 ipilimumab nivolumab pembrolizumab radiotherapy Review[ptyp] 
CTLA-4 
antigen 
Programmed cell death 1 
receptor 
CD274 ipilimumab nivolumab pembrolizumab abscopal Review[ptyp] 
 
Table 1: Search strategy with Boolean operators (AND, OR NOT). Parentheses () are placed where they appeared in the search. In addition, 
the filters English and Publication date from 2005/01/01 to 2016/12/31 were used.  
All searches were conducted in PubMed, after an iterative process of identifying relevant 
search-words. Finally the terms “abscopal”, “radiotherapy”, “CTLA-4 antigen”, “programmed 
cell death 1 receptor”, “CD274”, “ipilimumab”, “nivolumab” and “pembrolizumab” were 
combined in the searches shown in Table 1. Reviews were excluded, and the last search was 
run on the 13.05.2016. The three FDA-approved immune checkpoint inhibitors Ipilimumab, 
Nivolumab and Pembrolizumab (50), as well as their targets in the CTLA-4 or PD-1/PD-L1 
axis, were searched for.  
A conscious choice was made not to use Medical Subject Headings (MeSH), after preliminary 
searches with and without MeSH terms had identified inconsistent or absent tagging of 
relevant articles. A screening of titles showed that no articles were lost when not using 
MeSH terms, while several relevant articles turned up in the search without them.  
Article selection 
Articles were selected in a three-phased process, with initial screening of titles, thereafter 
screening of abstracts and finally a review of the full text articles passing the title and 
abstract screening. Articles deemed not eligible were excluded at each phase of the process.  
The process 
In the requirements for the 5. year thesis, it is stated that one should comment on the work 
process. The workflow consisted of 4 phases: 1) planning, 2) literature search and screening, 
3) reading and summarizing and finally 4) analysis and writing. Planning started at the end of 
2014, when my supervisor, Professor Inigo Z. Martinez, sent me a number of interesting 
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papers dealing with the immunomodulatory effects of RT. After some discussions about the 
subject with professor Martinez, this phase culminated when I wrote the project description 
in early 2015. Originally, the plan was to review clinical data on combinations of 
immunotherapy in general and radiotherapy. After early searches and screening in phase 
two, I made the decision to sharpen the focus of the thesis to deal with immune checkpoint 
inhibitors in particular, combined with radiotherapy. Early searches pointed to a relatively 
large amount of data available on this specific combination regimen, and a more thorough 
discussion is possible with a sharpened focus. Throughout my research year in autumn 2015 
and spring 2016, I read a number of papers dealing with subjects relevant to my 5th year 
thesis. My forskerlinje-project is an experimental project that deals with radiation and 
biological responses in cancer-associated fibroblasts. So while the projects are completely 
separate, both deal with cancer in general, and I have taken both a 10 study point master 
course, as well as a 10 study point PhD level course in cancer biology. Due to the earlier than 
planned immersion into relevant literature, I decided to deliver the thesis in spring 2016 
instead of 2017. Phase 2 and 3 overlapped during autumn 2015 and spring 2016, with a final 
search algorithm constructed in spring 2016, followed by systematic screening and reading 
of papers. After reading and summarizing the identified papers, the last phase consisted of 
analyzing the implications and potential future directions and writing the thesis. Professor 
Martinez gave feedback during the writing process.  
I have already been moved to MK-12 administratively, due to my research year. However on 
the front page, I have written MK-11, since I have registered for delivery of the 5th year 
thesis together with my old class (and in accordance with the old study plan). This was also 





The searches identified 103 unique entries 
in PubMed, but after application of 
eligibility criteria, 18 articles with clinical 
material for analysis were left; six case 
reports, nine retrospective studies and 
three prospective studies. The process of 
article screening is illustrated in Figure 1.  
In the identified case reports five patients 
suffered from advanced melanoma (51-55), 
and one patient from non-small cell lung 
carcinoma (NSCLC) (56).  The nine 
retrospective studies all dealt with advanced 
melanoma, including altogether 238 patients (range: 13-46 in each study) on relevant 
treatment regimens (57-65). An additional small prospective study (phase I) included 22 
melanoma patients (66). The two other prospective studies described patients with 
metastatic Castration Resistant Prostate Cancer (mCRPC). One of these studies was a 
combined phase I/II multicenter, open-label, non-randomized trial (67), while the other was 
a large phase III multi-center, double blinded, randomized controlled trial (68). The phase I/II 
trial included 71 patients, with 41 of them receiving combination treatment (67), while the 
phase III trial included 799 patients in the intention-to-treat analysis divided evenly between 
a) a combination regimen, and b) RT and placebo (68).  
The CTLA-4-inhibitor Ipilimumab was the only immune checkpoint inhibitor employed in all 
the reviewed studies. Doses ranged from 3-10 mg/kg of body weight, given in induction 
cycles every 3 weeks with a goal of four doses, and in some cases, maintenance doses every 
12 weeks, or re-induction (exact numbers of patients in each category are not available).  
Radiation for mCRPC was delivered to bone metastases (67, 68). The majority of the 
melanoma patients (n=183) received RT against brain metastases, divided between whole 
brain radiation therapy and/or stereotactic radiosurgery. Some (n=32) patients received RT 
to extracranial sites, including liver, bone, distant lymph nodes, skin, subcutaneous 
Fig. 1. Search results and work-flow. Reasons for exclusion after 




metastases, and lung (51, 54, 60, 66). One study did not break down the numbers of patients 
receiving extracranial irradiation and RT against brain metastases (65). Details from the case 
reports and studies are summarized in Tables 2, 3 and 4.  
Case reports  
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Metastatic 
melanoma 





PR: both IF 
and OF  











SD 16 months 
after Ipilimumab 
Bot et al 
2012 (52) 






Alive 18 months 
after Ipilimumab 
Du Four et 
al 2012 
(53) 
 57 M SABR: 54 Gy/3 Liver Ipilimumab: 3 
mg/kg  
Concurrent CR: IF and 
OF 
 
No evidence of 





 67 M SRS Brain  Ipilimumab  CR: IF and 
OF 
 
No evidence of 







64 M  IMRT: 30 Gy/5 Liver Ipilimumab 3 
mg/kg 
Concurrent CR: IF and 
OF 
 
No evidence of 






Table 2: Summary of findings in case reports with patients who has received combination therapies of immune checkpoint inhibitors and radiotherapy, and 
experienced abscopal responses. Abbreviations: M male, F female, IMRT intensity modulated radiation therapy, WBRT whole brain radiation therapy, SRS 
stereotactic radiosurgery, SABR stereotactic ablative radiotherapy, Gy Gray, RT radiotherapy, CR complete response, PR partial response, SD stable disease, IF 
in radiation field, OF out of radiation field 
  *Had one recurrence managed by surgery 
**Underwent an additional re-induction with Ipilimumab between the combination therapy and the complete regression  
 
In case report published in 2012, Postow et al. described a woman who started induction 
therapy with Ipilimumab against metastatic melanoma in September 2009, and who by the 
end of 2011 was in remission (51). She did not respond to induction therapy, but continued 
on maintenance therapy. Throughout 2010 she experienced radiographic worsening, with a 
paraspinal tumor mass undergoing progressive growth, and several new splenic lesions were 
detected in November 2010.  Due to back pain, she received palliative intensity-modulated 
RT to her paraspinal mass in December 2010, delivered in a dose of 28,5 Gy divided in 3 
fractions. A CT scan one month later, in January 2011, did not show responses in the 
irradiated site or any of the metastases. After an additional dose of Ipilimumab in February 
2011, a subsequent CT scan in April 2011 did showed a significant regression of her 
irradiated paraspinal mass, and in addition also regression of her other known metastases 
outside the radiation field. Ten months of follow-up after the RT, in December 2010, showed 
no subsequent progression of the tumor masses in CT-scans.  
Another case report from 2012, by Hiniker et al, reported a complete systemic response in a 
female patient with melanoma with metastases to the liver and a subcutaneous metastasis 
in the left arm (54). After detection of liver metastases on a PET-CT scan in May 2011, her 
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treatment team prospectively decided to combine CTLA-4 inhibition with radiotherapy to try 
to provoke an immunological anti-tumor response. PET-CT scans in August 2011 after the 
patient had received two doses of Ipilimumab, revealed an initial progression of the liver 
metastases, as well as development of several new ones. At this time, stereotactic 
radiotherapy of two of her liver metastases was delivered in a dose of 54 Gy divided in 3 
fractions. Initially a subcutaneous metastasis on her left arm rapidly appeared during the last 
cycles of Ipilimumab, but a PET-CT scan in December 2011 showed no uptake of 18F-
fluorodeoxyglucose in her liver metastases, indicating no metabolic activity in the tumor, 
and in late February 2012 the subcutaneous lesion had resolved as well. A PET-CT scan 1 
year after RT showed a complete regression of all liver metastases, including the non-
irradiated ones, as well as the lesion in the left arm, and the patient showed no evidence of 
any metabolically active malignancy.  
Complete systemic responses were also reported to occur twice in a male patient that first 
underwent fractionated RT in a palliative setting against melanoma of the head and neck, 
reported by Stamell et al. in 2013 (55). Within 8 months of RT, both his irradiated tumor and 
all his additional known metastases had resolved completely. However, after 36 months 
brain and nodal metastases were detected, and the patient was treated with stereotactic 
radiosurgery to the brain and Ipilimumab. Subsequently a remarkable complete remission 
occurred, with the patient being alive 4 years after the combination therapy. A recurrence in 
a cervical lymph node was managed surgically, but no other metastases appeared in the 
period of follow-up.   
Treatment with stereotactic radiosurgery and Ipilimumab also preceded a treatment 
response in a male melanoma patient with brain metastases, described by Du Four et al. in 
2012 (53). The patient received stereotactic radiosurgery against two lesions in the brain, 
followed by extracranial progression detected three months later. Ipilimumab induction was 
started three months later, and a complete response outside the brain subsequently 
developed, as documented with PET-CT scans. The irradiated brain lesions underwent 
gradual regression, and one lesion disappeared completely. However, two years after 
stereotactic radiosurgery a lesion surrounded by edema reappeared in the same spot, 
accompanied by headache. This led to a surgical resection of the lesion, and histology 
revealed necrosis and gliosis, with no viable melanoma cells or inflammatory cells. Eighteen 
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months after Ipilimumab initiation no extracranial recurrence was detected, the remaining 
CNS lesions were stable, and the patient stayed in a stable neurological condition. The 
authors published this case report together with two other cases, including two females with 
melanoma with brain metastasis, where the patients also experienced radiation necrosis 
after RT and Ipilimumab, and the focus of the paper was on radiation necrosis. All three 
patients responded favorably to treatment. However, the last two patients did receive 
potentially confounding chemotherapy and dendritic cell based immunotherapy and are 
therefore not discussed thoroughly in the present thesis.  
Whole brain RT in combination with Ipilimumab was reported by Bot et al. to precede a 
response in a female patient with lung metastases and leptomeningeal metastases of 
melanoma, exhibiting morning headache, nausea and vomiting (52). She received whole 
brain RT in 4 fractions followed by 4 courses of Ipilimumab. Already after the first course of 
Ipilimumab her headache, nausea and vomiting disappeared, and after all four courses the 
radiological signs of leptomeningeal metastases had disappeared. Her non-irradiated lung 
metastases underwent a partial response, and in the last follow-up 1,5 years after the start 
of Ipilimumab treatment the lung tumors were stable. Magnetic resonance imaging 
presented no evidence of leptomeningeal metastases. 
While the five case reports described so far all dealt with patients suffering from melanoma, 
Golden et al published a report in 2013 on a male suffering from NSCLC (56). The patient 
suffered from widespread metastatic disease, with several lesions in the lungs, liver, bone, 
and hilar/mediastinal adenopathy and periaortic adenopathy. The patient was offered RT 
and Ipilimumab with the prospective goal of triggering an abscopal response. Intensity 
modulated RT in a dose of 30 Gy were delivered in 5 fractions over 10 days, with Ipilimumab 
induction starting the day after the first dose of radiation. Following the treatment that 
started in August 2012, posttreatment chest CT and PET-CT scans were conducted in 
November 2012 and January 2013, respectively. The patient experienced responses in both 
irradiated lesions, as well as the non-irradiated ones, and the levels of the non-specific 
tumor-marker carcinoembryonic antigen dropped dramatically. A metastasis in a lymph 
node was detected and excised, and another additional four cycles of Ipilimumab were 
administered from June 2013 to August 2013. PET-CT in September 2013, 1 year after 
combination therapy revealed no evidence of disease.  
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Table 3: Summary of findings in studies on advanced melanoma patients who has received combination therapies of immune checkpoint inhibitors and 
radiotherapy. Abbreviations: N number of patients, SRS stereotactic radiosurgery, WBRT whole brain radiotherapy, RT radiotherapy, SABR stereotactic ablative 
radiotherapy, Gy Gray, NA not available  
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In three of the identified studies on metastatic melanoma and combination treatments with 
RT and Ipilimumab, matched control groups not receiving Ipilimumab were included (57-59). 
These studies all dealt with RT against brain metastases. The study by Knisely et al. (57) 
found a MS of 21,3 months in a cohort treated with stereotactic radiosurgery and 
Ipilimumab (n=27) compared with 4,9 months in a cohort treated with SRS alone (n=50) (HR 
0,61 p=0,102). The 2-year survival rate was 47,2% in the Ipilimumab group and 19,7% in the 
control group. While the cohorts were generally well matched, including in prognostic 
scores, performance status, and sex, the group receiving Ipilimumab was significantly 
younger. There was also a trend towards higher use of additional targeted therapy in the 
group receiving Ipilimumab. In a study published by Silk et al. (59) another cohort of 33 
patients who received Ipilimumab together with either stereotactic radiosurgery (n=17) or 
whole brain RT (n=16) was compared against a cohort who received either stereotactic 
radiosurgery (n=16) or whole brain radiotherapy (n=21) alone. MS for the group who 
received RT and Ipilimumab was 18,3 months, as compared with 5,3 months for the group 
that received RT alone (HR 0,43 p=0,005). There was significantly higher use of inhibitors of 
the BRAF oncoprotein in the group receiving Ipilimumab and a higher rate of additional RT to 
the brain, whereas there were trends towards lower performance status and more 
neurological symptoms in the group of patients that did not receive Ipilimumab. Otherwise, 
the groups were well matched. The third of these studies compared a cohort treated with 
stereotactic radiosurgery and Ipilimumab (n=25) to a cohort treated with only stereotactic 
radiosurgery (n=33). Primary endpoints were 6-month local control of metastases treated 
with stereotactic radiosurgery, 6-month freedom from new brain metastases and 6-month 
overall survival. Respective rates for the group treated with Ipilimumab and the group 
without were 63% and 65% for local control (p=0,55), 35% and 47% for freedom from new 
brain metastases (p=0,48) and 56% and 45% for overall survival (p=0,18) (58). Thus, there 
was no significant benefit of adding Ipilimumab to stereotactic radiosurgery in this study. 
The median survival after RT for both cohorts combined was 5,9 months (58).  
Tazi et al. (64) explored a different angle, by comparing patients with brain metastases at 
treatment start with Ipilimumab (n=10) with patients without brain metastases (n=21). The 
authors found that patients who received RT and Ipilimumab against brain metastases did 
not live significantly shorter than advanced melanoma patients without brain metastases 
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who received Ipilimumab. MS from cycle 1 of Ipilimumab was 16,5 months for the cohort 
with brain metastases and 24,5 months for the one without (HR 1,05, p=0,931), estimated 3-
year survival rates were 50% and 39% respectively. Seven patients in the cohort without 
brain metastases at treatment start with Ipilimumab did subsequently develop them, and six 
eventually received stereotactic radiosurgery (64).  
Two studies did not include control groups that did not receive either RT or Ipilimumab. 
Gerber et al. (61) explored whole brain RT combined with Ipilimumab. MS was lowest of all 
identified studies in this cohort (n=13), at only 4 months, with 1 year survival rate of 15,4% 
(61). Kiess et al. (62) published a study with the largest cohort of melanoma patients with 
brain metastases, including 46 patients who received stereotactic radiosurgery and 
Ipilimumab. The MS was 12,4 months (62).  
Three of the retrospective studies specifically looked for abscopal effects following radiation. 
Grimaldi et al. (60) identified 21 patients who had received RT 3,4-8 months after initiation 
of Ipilimumab treatment, 13 of them with radiation against brain metastases and 8 against 
extracranial sites. 13 patients experienced a local response to RT, while 9 of these 
experienced a partial response outside of the radiation field and 2 had stable disease for 
more than 3 months. No patients without a local response had abscopal responses. MS for 
abscopal responders was 22,4 months vs 8,3 months (p=0,002), correlating the responses to 
a survival benefit. MS overall was 13 months. Median time to abscopal response was 1 
month (range 1-4). Schoenfeld et al. (63) identified 16 patients treated with Ipilimumab and 
stereotactic radiosurgery and/or whole brain RT against brain metastases. By designating the 
largest extracranial lesion found radiographically on images taken before RT as an index 
lesion, they followed this lesion for effects after RT. In 35% of instances where images were 
available before and after RT, the index lesion decreased in size. As a comparison, most of 
these patients had two consecutive scans available before RT, and only 17% of these showed 
a regression without RT in between. MS for the entire cohort was 14,4 months. Chandra et 
al. (65) reported the largest cohort overall for melanoma patients, with 47 patients receiving 
RT to the brain as whole brain RT or stereotactic radiosurgery, or extracranially to spine, 
bone, soft tissue, abdominovisceral and intrathoracic. Survival for the entire group was 28 
months, with a 5-year survival rate of 20%. By using the same method as Schoenfeld et al. 
they found abscopal shrinkage of their index lesion in 25% of the cases following RT, 
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compared 11% of cases without RT in between radiographic scans. Median time to response 
was <1 month.  
The single prospective study, included in the present review, was a phase I clinical trial 
(NCT01497808), including 22 patients, combining stereotactic ablative RT regimens of 8 Gy x 
2-3 against bone/lung metastases or 6 Gy x 2-3 against liver/subcutaneous lesions with 
subsequent Ipilimumab 3 mg/kg. Evaluation of non-irradiated lesions revealed partial 
responses in 18% of the patients, stable disease in 18% and progressive disease in 64%. MS 
was 10,7 months (66). 
In general, combinations of Ipilimumab and RT is reported to give side effects comparable to 
Ipilimumab alone (23). Some cases of radiation necrosis with surrounding cerebral edema 
did need surgical management, however (53, 57, 62). Some studies reported intracranial 
hemorrhages following radiation (58, 61), but apparently this occurs in untreated brain 
metastases as well (69, 70).  
Studies on patients with metastatic castration resistant prostate cancer 
Design Radiation regimen, 
dose/fractions 








RT + placebo 
Ref. 






Focal RT (n=42): 8 Gy 
each for 1-3 lesions 
 
Bone  Ipilimumab(n=70): 3, 5 










blind, phase III trial 
(intention to treat; 
n=799) 
Focal RT (n=799): 8 
Gy each for 1-5 
lesions 











Table 4: Studies on patients with metastatic castration resistant prostate cancer who has received combination therapies of immune checkpoint inhibitors and 
radiotherapy: Abbreviations: RT radiotherapy   
The earliest identified study on mCRPC dealing with RT and Ipilimumab was a non-
randomized open-label multicenter phase I/II study (67), with an initial dose escalation 
phase gradually assigning patients to 3, 5 or 10 mg/kg of Ipilimumab and after accrual 3 or 
10 mg/kg and RT. All patients had evidence of progression after discontinuation of anti-
androgen therapy. For the phase II part, the cohort of 10 mg/kg with and without RT were 
expanded to 50 patients, divided into 16 patients that did not receive RT and 34 patients 
receiving RT. The RT was given as a focal dose of 8 Gy against each of 1-3 bone metastases 
24-48 hours before Ipilimumab. Overall survival for all cohorts was 17,4 months, with the 
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survival for each cohort not reported. In the phase II part there was one complete response 
(13%) and one instance of stable disease (13%) in the non-irradiated group, and five 
instances of stable disease (25%) in the irradiated group. The stable disease states lasted 
from 2,8-6,1 months, while the complete response lasted 11,3 months before censoring.  
The second study in mCRPC was a multicenter, randomized, double, blind, phase III trial, 
where the intention to treat analysis included 799 patients (68). These were divided into two 
arms comparing RT and placebo against RT combined with 10 mg/kg of Ipilimumab. Again, 
radiation was directed against bone metastases, with 8 Gy per lesion, delivered within 2 days 
before Ipilimumab initiation. One to five lesions were irradiated. MS was 11,2 months in the 
Ipilimumab group and 10,0 in the placebo group. The hazard ratio was 0,85 (p=0,053), but 
the proportional hazards assumption was violated, making it invalid. One year overall 
survival was 46,8% to 40,4%, respectively. Two year survival was 26,2% to 15,0%, but a large 
proportion of patients were censored before two years. Prespecified subgroups with good 
prognostic features did experience a survival benefit in the Ipilimumab arm.  
In both studies, adverse effects were common, but mostly managed by corticosteroids, 
endocrine replacement therapy and other supportive care (67, 68). In the first study one 
patient died of aspergillosis after 4 months of immunosuppression for managing colitis (67), 
and less than 2% of the deaths in the second study were considered to be related to 





Evidence for synergy  
It is difficult to ascertain to what extent the treatment responses described in the case 
reports represents true synergism between RT and immune checkpoint inhibition. Three of 
the articles included immunological correlates to the treatment (51, 55, 56). In the case 
reported by Postow et al. (51), titers of antibodies against the entire protein NY-ESO-1 (a 
cancer antigen (71)) steadily increased throughout the development of the disease, while 
beginning to fall concurrent with resolution of the disease. Such a reduction in anti-NY-ESO-1 
antibodies concurrent to reductions in tumor burden have been reported earlier (72). 
Interestingly, immediately following RT titers of antibodies against an epitope or epitopes on 
the central portion of the protein increased by a factor of over 30, which may indicate a 
vaccine-like response to RT. However, antibodies against other epitopes on NY-ESO-1 
increased before RT, and it is not completely clear what the changes in antibody titers 
implicate. In a another correlate consistent with a vaccine-like effect of RT, analysis of blood 
samples identified 10 antigens with increased responses mounted against them by 
antibodies after treatment (51). 
In the same patient (51), flow cytometry of peripheral blood monocytes performed at 
different time points found an increase in CD4+ ICOShigh cells (ICOS is a marker for T-cell 
activation (73)) and HLA-DR (a MHC-II molecule) expression on CD14+ monocytes (marker 
found on dendritic cells and macrophages, which could serve as APCs (74)) concurrent with 
Ipilimumab induction. However, this was followed by a subsequent decrease in these 
markers, and was not associated with treatment responses. After RT new increases in CD4+ 
ICOShigh cells and HLA-DR+ CD14+ monocytes were detected, but this time also accompanied 
with a marked decline in myeloid derived suppressor cells. This fall preceded the regression 
of the tumor masses of the patient. That there were increases in numbers of activated CD4+ 
T cells and HLA-DR+ monocytes correlated to both Ipilimumab induction and RT, could 
suggest that both treatment modalities did elicit desired immunological responses, but for 
some reason the immunological responses after Ipilimumab induction were ineffective at 
combating the cancer until RT was applied. Likewise, that the numbers of myeloid derived 
suppressor cells decreased following RT may be a sign that RT did play a role in driving the 
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immunological anti-tumor response. Overall, the timing, with the lack of response to initial 
Ipilimumab-treatment, 14-months of radiographic progression during maintenance therapy, 
followed by RT and one additional dose of Ipilimumab and then the dramatic response, also 
presents circumstantial hints of synergy between Ipilimumab and RT. One phase III 
randomized controlled trial, including Ipilimumab alone in one of the treatment arms, had a 
mean time to response of 3,18 months (23). However, the same randomized controlled trial 
as well as another phase III trial also observed changes in responses as late as beyond 6 
months (23, 24). One patient described in 2014 showed an anti-tumor response 11 months 
after therapy initiation with Ipilimumab (75), so one cannot completely dismiss an 
independent delayed response to Ipilimumab. Ruling out an abscopal effect of radiation, not 
dependent on Ipilimumab therapy, is also unfortunately impossible based on the available 
data.  
Stamell et al. (55) also reported immunological correlates in their case report. Before 
combination therapy with RT and Ipilimumab, the patient had already experienced an 
abscopal response by RT alone, and preexisting antibodies against melanoma antigen A3 
(MAGEA3) were already present before combination therapy. Titers of these antibodies 
measured by enzyme-linked immunosorbent assay (ELISA) showed a marked increase 
following RT and Ipilimumab treatments, and a new response against the cancer antigen PAS 
containing domain 1 (PASD-1) was detected. These correlates are consistent with a vaccine-
like effect of RT, but due to the lack of markers specifically associated with responses to 
Ipilimumab, they do not in themselves present conclusive evidence for synergy.  
The last patient with immunological correlates was the patient reported by Golden et al. 
(56), who suffered from NSCLC. His absolute lymphocyte counts and eosinophil counts 
increased significantly during treatment with Ipilimumab and RT. Such increases are 
associated with prolonged survival in melanoma patients treated with Ipilimumab (76-80), 
and could suggest that Ipilimumab was implicated in anti-tumor responses. Two lymph node 
metastases excised in 2010 and 2013, before and after combination treatment, had notably 
different histological patterns of immune-cell infiltration. In the first biopsy, lymphocytes 
were concentrated in perivascular areas of the tumor, while in the newly excised one, there 
was lymphocyte infiltration into tumor nests. They found more CD8 and TIA-1 (marker for 
cytotoxic granules (81)) positive cells in the latest biopsy, and while FoxP3+ (marker for Treg`s 
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(82)) cells were also more common, the ratio of CD8/FoxP3 cells was higher (56). This 
pattern of lymphocyte infiltration is consistent with preclinical data on effective CTLA-4 
inhibition (83).  
Immunological correlates indicating effective anti-tumor responses after CTLA-4 inhibition in 
NSCLC are interesting, due to earlier data on the lack of effect of CTLA-4 inhibition alone in 
this cancer type. A phase II trial testing the anti-CTLA-4 mAb Tremelimumab as monotherapy 
against locally advanced or metastatic NSCLC found no significant benefit in progression-free 
survival compared with standard platinum-based cytotoxic therapy (84). Another phase II 
trial compared standard cytotoxic treatment and placebo against cytotoxic treatment and 
Ipilimumab. A phased regimen of cytotoxic treatment followed by Ipilimumab did achieve a 
significantly improved immune-related progression free survival, with a concurrent 
treatment showing no difference from the control (85). One interpretation put forth by the 
authors of the paper was that CTLA-4 inhibition alone is ineffective against NSCLC, but 
cytotoxic chemotherapy creates a vaccine effect that primes T cells for action, and 
synergizes with CTLA-4 inhibition, removes suppression of T cells (85). The impressive effect 
of RT combined with Ipilimumab in the case report could be consistent with such a model, 
with the RT filling the role of priming T cells with tumor antigens and danger signals (56). 
Still, ruling out a therapeutic effect of Ipilimumab alone is not possible. Especially since the 
study showing no effect of monotherapy used Tremelimumab (85), which could simply be 
less effective than Ipilimumab, despite inhibiting the same signaling axis.  
Despite uncertain causal factors for the anti-tumor responses, all six patients in the reviewed 
case reports (51-56) experienced impressive regression of advanced cancer with typically 
bleak prognoses. For instance, a retrospective study on melanoma patients with 
leptomeningeal metastases, where 77,5% had received treatment with radiation and/or 
chemotherapy, reported a MS of only 10 weeks, with 1 and 2 year survival rates 7% and 3%, 
respectively (86). This stands in contrast to the 16 months of radiographically stable disease 
and clinical remission experienced by the patient described by Bot et al (52). The timing and 
immunological correlates in the case reports, when available, presents some indications for 
speculating that there were synergistic effects of RT and immune checkpoint inhibition in 
some of these cases. Of note, six patients is too few for making many inferences. However, 
larger patient materials are starting to become available. The seven identified retrospective 
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studies on advanced melanoma with brain metastases, discussed in the present review, 
reported a MS ranging from 4-21,3 months, with all but two studies (n=38) (58, 61) reporting 
a MS over 1 year(57, 59, 62-64). This is generally higher than MS reported in earlier material 
without combination regimens of RT and immune checkpoint inhibition in patients with 
brain metastases.  
One retrospective study from the Sydney Melanoma Unit, on 686 patients treated between 
1985-2000 for melanoma with brain metastases, reported an overall MS of 4,1 months, with 
a MS of 8,9 months for patients treated with surgery and RT, and 3,4 months for RT alone 
(87). Other studies confirm the bleak prognosis of melanoma patients with brain metastases 
(88, 89). Retrospective studies of patients treated with stereotactic radiosurgery reports MS 
below 8 months (90-92). With the retrospective studies at hand it is difficult to answer 
conclusively whether the better than expected survival in five of the seven studies on 
combination treatments with RT and Ipilimumab in melanoma patients with brain 
metastases represent true treatment benefits, or biases in the studies.  
If the improved survival found is indeed generalizable, another difficult question is what the 
causal mechanisms are. The limited clinical benefit of RT without immune checkpoint 
inhibition in previously reported cohorts could perhaps support that Ipilimumab is 
implicated in improving survival. Whether this is a synergistic or even additive effect 
together with RT is difficult to assess. A systematic review extracting data from 14 studies on 
melanoma patients with brain metastases treated with immune checkpoint inhibitors, found 
a MS of 7,0 months in clinical trials and 4,3 months in real world studies (93). This is below 
the MS reported in most of the studies reviewed here, which could support a benefit of 
combination therapy over Ipilimumab, but no solid conclusion can be drawn from 
comparisons between heterogeneous cohorts.  
For patients with extracranial metastases, the single identified prospective study on 
advanced melanoma did not report treatment benefits very different from Ipilimumab 
without radiation (25, 66). However, the retrospective study of Chandra et al. (65) found a 
very solid MS of 28 months (also including an unspecified number of patients with brain 




The three studies on melanoma that specifically looked for abscopal effects after RT, 
reported rates of 52%, 35% and 25% of included patients with responses outside of the 
irradiated field (60, 63, 65). In addition, the study in ref. (60) did not only show an increased 
survival for abscopal responders. Here, a local response to radiation turned out to be highly 
predictive of such a response, which may suggest that RT is implicated in the improved 
survival. Patients were also followed for absolute lymphocyte counts from before 
Ipilimumab initiation. At baseline, the groups were similar, but the abscopal responders had 
significantly higher absolute lymphocyte counts during Ipilimumab induction and before RT 
(60).The lymphocyte counts did show patterns associated with improved survival after CTLA-
4 inhibition (76-80), which could perhaps suggest a role for Ipilimumab treatment in 
improving survival as well. The large percentages of abscopal responders also serve as hints 
that synergy with RT and Ipilimumab is implicated, given the typical rarity of abscopal 
responses after RT alone (34, 35). As mentioned earlier, two of these studies included 
internal controls to validate that the rate of abscopal responses found, was not simply due 
to actively looking for the phenomena (63, 65). 
The studies on mCRPC did overall not provide conclusive evidence supporting the combined 
treatment (67, 68). This does not necessarily need to be evidence against the general 
soundness of combining immune checkpoint inhibition and RT. It could for instance be that 
the treatment is not well suited for the cancer type. Data from two studies on melanoma 
suggests that a high mutational load in the tumor is correlated with, but not necessary for, a 
clinical response to CTLA-4 inhibition (94, 95). There is evidence that mutational loads, as 
well as the specific mutations present, varies between cancer types (96). This could present 
a basis for different responses between melanoma and mCRPC-patients. Another possibility 
is that the radiation regimen was suboptimal.  
Radiation regimen and timing  
In both papers on mCRPC the authors state that the dose of 8 Gy in one fraction per lesion 
was selected due to proven benefits for pain palliation (67, 68). It does not appear that there 
was a focus on optimizing the radiation for a desired immunological effect. Preclinical 
experiments in mice with mouse breast carcinoma cells and mouse colon carcinoma cells by 
Dewan et al. (97) explored the effect of doses and fractionation of RT. They found that CTLA-
4 inhibition together with fractionated regimens of 8 Gy x 3 and 6 Gy x 5 exhibited 
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considerable anti-tumor synergy on both a primary irradiated tumor, and in an abscopal 
manner on a secondary non-irradiated tumor. A single dose of 20 Gy failed to do so, while 8 
Gy x 3 was especially effective. Controls with RT alone and anti-CTLA-4 alone had only local 
or no effect, respectively. However, it is unclear how transferable dosing and fractionation 
data is from animals to humans (98). 
Some of the identified papers described the exact radiation doses and fractionation for 
altogether 14 patients with complete or partial abscopal responses (51-54, 56, 60). In the 
identified case reports three of the patients received extracranial regimens of 18 Gy x 3, 9,5 
Gy x 3 and 6 Gy x 5 (51, 54, 56), while one received whole brain RT of 4 Gy x 5 (52). 
Stereotactic radiosurgery was performed with a dose of 20 Gy x 1 in one case (53). Grimaldi 
et al. (60) described the radiation regimens preceding the 9 abscopal partial responses in 
their study, which were whole brain RT 3 Gy x 10 in four patients, stereotactic radiosurgery 
20-24 Gy x 1 in three patients, and extracranial regimens of 2 Gy x 25 and 4 Gy x 5 in one 
patient each. So overall, the doses and fractionation varied, with fractionated RT preceding 
the abscopal response in 10 cases (51, 52, 54, 56, 60) and unfractionated in 4 cases (53, 60). 
In one case report with a complete systemic response stereotactic radiosurgery is reported, 
but without any specifications about dose or fractionation (55). In addition to the studies 
describing exact regimens, Chandra et al. found a significant association between radiation 
fractions of ≤ 3 Gy and shrinkage of non-irradiated lesions. While most of the abscopal 
responses occurred after fractionated radiation, some followed single fraction stereotactic 
radiosurgery, and it is unclear from the data what the optimal radiation regimens should be. 
This may vary between target tumors and sites, as well. An interesting question is whether 
immunological responses to radiation are similar in the brain and outside the CNS. Radiation 
doses and fractions in the articles on melanoma patients are summarized in Tables 2 and 3, 
when available. 
The sequencing could also have ramifications for effective treatment. In their 
aforementioned preclinical model, Dewan et al also found that concurrent treatment were 
superior to delayed checkpoint inhibition after RT (97). However, the clinical data is mixed 
on this. Knisely et al. (57) found no significant difference in MS between Ipilimumab before 
or after RT, and Mathew et al. (58) reported no significant difference in incidence of new 
brain metastasis between concurrent therapy and Ipilimumab before RT. Supporting this 
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Chandra et al. (65) found no impact for timing on the frequency of abscopal responses. Silk 
et al. (59) found improved survival for patients treated with RT before Ipilimumab compared 
with after. Kiess et al. (62) reported higher 1-year survival for concurrent treatment or RT 
before Ipilimumab compared to RT afterwards. Schoenfeld et al. (63) also found longer 
survival in patients undergoing concurrent treatment or RT prior to Ipilimumab, compared to 
Ipilimumab prior to stereotactic radiosurgery. They also found a significantly higher rate of 
abscopal responses when Ipilimumab was delivered within a three months window 
surrounding radiotherapy. However, in the cohort of Grimaldi and colleagues (60) all 
patients received RT after Ipilimumab, while many still experienced favorable outcomes. 
While there might be a trend in the data towards concurrent treatment or radiotherapy first, 
interpretations could be skewed by selection bias. Patients who have to receive RT after 
Ipilimumab might experience quicker progression, or they may respond less to immune 
checkpoint inhibition, as suggested by Kiess et al. (62).   
Future prospects 
While there is some clinical evidence for apparent synergy between RT and CTLA-4 inhibition 
with Ipilimumab, in particular from case reports and the studies on abscopal responses 
following RT, there is still a lot of unknowns with regard to optimal treatment regimens. 
Increased knowledge about the mechanics of interaction will prove helpful for designing 
treatment algorithms for dosing and sequencing, and current knowledge about these 
mechanics has recently been reviewed thoroughly elsewhere (99, 100). 
Other interesting avenues of research are the exploration of other immune checkpoint 
inhibitors than Ipilimumab, and studies on combinations with additional treatments. Zeng et 
al. found improved survival in a mouse model of glioblastoma multiforme by combining a 
single fraction of 10 Gy with inhibition of the PD-1 receptor with a mAb (101). Dovedi et al. 
also explored the PD-1/PD-L1 axis in several mice models, including a colon carcinoma, a 
melanoma and a breast cancer cell line (102). Radiotherapy delivered as 10 Gy in 5 fractions, 
here led to an increase in expression of PD-L1 on tumor cells, which could be responsible for 
resistance to immune attack after RT (102). A small retrospective cohort from humans with 
head and neck cancer supports these data (103). Chemoradiotherapy was associated with a 
significantly higher PD-L1 expression, while chemotherapy alone correlated to a decrease in 
expression, suggesting that RT could be responsible for the increase (103). Dovedi and 
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colleagues combined the fractionated RT regimen with mAbs against both PD-L1 and PD-1, 
which led to complete responses in 66% and 80% of the mice (103). In addition, they 
explored timing of the treatments, and found that delaying checkpoint inhibition for too long 
abrogated the effects (102). Other preclinical studies have also found both local and 
abscopal synergism for PD-1/PD-1L inhibition and RT (104-106). Impressive rates of complete 
responses and improved survival was found in mice models treated with double blockade of 
both CTLA-4 and PD-1/PD-L1 together with radiotherapy (66). A recently published phase III 
trial in patients with metastatic melanoma found significantly increased progression-free 
survival and fewer treatment-related adverse effects in patients receiving the PD-L1/2 
inhibitor Pembrolizumab, compared to patients receiving Ipilimumab (28). These results 
makes possibilities of combination regimens with PD-1 axis inhibition and RT extra exciting.  
In yet another preclinical combination regimen Belcaid et al. explored a triple therapy of RT, 
CTLA-4 inhibitor and a CD137 agonist (a co-stimulatory receptor, also known as BB4-1 (107)) 
in a glioblastoma model. Survival was improved compared to single therapies of each, or 
combinations of a) CTLA-inhibition and RT or b) CD137 agonism and RT (108). Another study 
in a BRAFV600 mutant melanoma model in mice found anti-tumor effects of stereotactic 
ablative radiotherapy, PD-1 blockade and CD137 agonism (109).   
While novel combination therapies offer exciting prospects, randomized controlled trials are 
needed to conclusively prove the efficacy of a combination regimen. Several clinical trials are 
recruiting patients for combinations of radiotherapy and PD-1/PD-L1 axis inhibition, 
including phase II randomized controlled trials exploring stereotactic ablative radiotherapy 
and Pembrolizumab in NSCLC (NCT02444741 (110)) and stereotactic ablative radiotherapy 
and Nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT02684253 (111)). 
For treatments with Ipilimumab, the University of Michigan Cancer Center is recruiting 
patients for a phase II RCT for melanoma with brain metastases, comparing stereotactic 
radiosurgery before Ipilimumab to Ipilimumab before stereotactic radiosurgery 
(NCT02097732 (112)), which can prove illuminating for sequencing of treatments. 
Limitations to the study 
This review have dealt with studies including heterogeneous designs, populations and 
treatment regimens, which made direct comparisons challenging. In addition, responses 
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were examined with non-homogenous criteria, with different studies using RECIST, WHO-
criteria and immune related response criteria (4-6). Where preclinical studies have been 
mentioned to inform the discussion, differences between animal and human biology can 
serve as a source of confounding (98). Most of the studies are single case studies and 
retrospective cohorts. Generalizations from such studies should be approached with caution, 
due to inherent risks of selection biases in the patients included. Many patients included in 
several of these studies were enrolled in clinical trials, with frequent follow-ups, which could 
cause a lead-time bias, with earlier detection of for instance brain metastases, and longer 
follow-up subsequently misinterpreted as increased survival (57, 62). There might also be 
publication biases, where material showing interesting correlations is preferentially 
published over negative results. Selection of articles for the review was performed alone by 
one author, which could serve as a source of bias. Often several authors do this process, and 
a single person might unconsciously pick articles in line with personal hypotheses. Finally 
only a single database has been used for the search, which might lead to the omission of 
relevant articles.  
Conclusion 
Several preclinical models have shown clear synergistic effects of combinations of 
radiotherapy and immune checkpoint inhibition (48, 66, 97, 101, 102, 104-106, 108, 109), 
and circumstantial evidence from case reports and retrospective studies are accumulating 
for similar phenomena in humans (51-56, 60, 63, 65). There are still a number of questions 
left regarding factors such as doses and fractionation of radiotherapy, as well as timing of 
treatments (99, 100). The single identified large RCT for patients suffering from metastatic 
castration resistant prostate cancer did not show improved survival for patients treated with 
radiotherapy and CTLA-4 inhibition (68), but non-randomized studies in melanoma patients 
are overall more encouraging (57-66). However, to prove conclusively if synergistic 
treatments with radiotherapy and immune checkpoint inhibitors are feasible in larger 
patient populations randomized controlled trials with appropriate controls have to be 
conducted. Further preclinical work may also be needed to illuminate the mechanisms 
underlying the interplay between radiation and immune checkpoint inhibition, and help 
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